Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 29;12(4):819.
doi: 10.3390/cancers12040819.

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Anna Diana  1 , Francesca Carlino  1 , Elisena Franzese  1 , Olga Oikonomidou  2 , Carmen Criscitiello  3 , Ferdinando De Vita  1 , Fortunato Ciardiello  1 , Michele Orditura  1
Affiliations
Review

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Anna Diana et al. Cancers (Basel). .

Abstract

Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population.

Keywords: PARP inhibitors; biomarkers; immunotherapy; neo-(adjuvant); triple negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Garrido-Castro A.C., Lin N.U., Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019;9:176–198. doi: 10.1158/2159-8290.CD-18-1177. - DOI - PMC - PubMed
    1. Diana A., Franzese E., Centonze S., Carlino F., Della Corte C.M., Ventriglia J., Petrillo A., De Vita F., Alfano R., Ciardiello F., et al. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. Curr. Oncol. Rep. 2018;20:e76. doi: 10.1007/s11912-018-0726-6. - DOI - PubMed
    1. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular Portraits of Human Breast Tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093. - DOI - PubMed
    1. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., He X., Perou C.M. Phenotypic and Molecular Characterization of the Claudin-Low Intrinsic Subtype of Breast Cancer. Breast Cancer Res. 2010;12:R68. doi: 10.1186/bcr2635. - DOI - PMC - PubMed
    1. Hu Z., Fan C., Oh D.S., Marron J., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:e96 - PMC - PubMed